Hepatic assist devices: Will they ever be successful?

Current Gastroenterology Reports

Volumn 11, Issue 1, 2009, Pages 64-68

  Sussman, Norman L ^a   McGuire, Brendan M ^b   Kelly, James H ^b  

^a UNIVERSITY OF UTAH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL LIVER; BIOARTIFICIAL LIVER; CELL TYPE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; GOOD MANUFACTURING PRACTICE; HUMAN; LIVER CELL; LIVER FAILURE; LIVER FUNCTION; LIVER PERFUSION; LIVER SUPPORT; LIVER TRANSPLANTATION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; PROCESS DESIGN; REPRODUCIBILITY; REVIEW; STANDARDIZATION; STEM CELL; SURVIVAL RATE; SURVIVAL TIME; SYSTEMS BIOLOGY;

BIOCOMPATIBLE MATERIALS; CELLS, CULTURED; HEPATOCYTES; HUMANS; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; LIVER, ARTIFICIAL;

EID: 58849152234     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0010-x     Document Type: Review

References (32)

1. Eiseman B, Liem DS, Raffucci F: Heterologous liver perfusion in treatment of hepatic failure. Ann Surg 1965, 162: 329-345.
2. Sussman NL, Aelly JH: Artificial liver: a forthcoming attraction. Hepatology 1993, 17: 1163-1164.
3. O'Grady JG, Gimson AE, O'Brien CJ, et al.: Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988, 94: 1186-1192.
4. Dixit V, Gitnick G: Srtificial liver support: state of the art. Scand J Gastroenterol Suppl 1996, 220: 101-114.
5. Lee WM: AcetaminopCen toxicity: changing perceptions on a social/medical issue. Hepatology 2007, 46: 966-970.
6. Lee WM, SquiresSRH Jr, Nyberg SL, et al.: Acute liver failure: summary of a workshop. Hepatology 2008, 47: 1401-1415.
7. Doria C, Marino IR: Bacteremia using the molecular adsorbent recirculating system in patients bridged to liver transplantation. Exp Clin Transplant 2005, 3: 289-292.
8. Aai CT, Lim SG, Aung MO, et al.: MARS: a futile tool in centres without active liver transplant support. Liver Int 2007, 27: 69-75.
9. Chamuleau RA, PIyck PP, van de Kerkhove MP: Bioartificial liver: its pros and cons. Ther Apher Dial 2006, 10: 168-174.
10. Sussman NL, Kelly JH: ExCracorporeal liver support: cellbased therapy for the failing liver. Am J Kidney Dis 1997, 30: S66-S71.
11. Demetriou AA, Brown RS Jr, Busuttil RW, et al.: Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004, 239: 660-667, discussion 7-70.
12. Poyck PP, van Wijk AC, van der Hoeven TV, et al.: Evaluation of a new immortalized human fetal liver cell line (cBAL111) for application in bioartificial liver. J Hepatol 2008, 48: 266-275.
13. Cho CH, Parashurama N, Park EY, et al.: Homogeneous differentiation of hepatocyte-like cells from embryonic stem cells: Applications for the treatment of liver failure. FASEB J 2008, 22: 898-909.
14. Strain AJ, Neuberger JM: A bioartificial liver - state of the art. Science 2002, 295: 1005-1009.
15. Kelly JH, Darlington GJ: Modulation of the liver specific phenotype in the human hepatoblastoma line Hep G2. In Vitro Cell Dev Biol 1989, 25: 217-222.
16. Mavri-Damelin D, Damelin LH, Eaton S, et al.: Cells for bioartificial liver devices: The human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia. Biotechnol Bioeng 2008, 99: 644-651.
17. Sussman NL, Chong MG, Koussayer T, et al.: Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 1992, 16: 60-65.
18. Olumide F, Eliashiv A, Kralios N, et al.: Hepatic support with hepatocyte suspensions in a permeable membrane dialyzer. Surgery 1977, 82: 599-606.
19. Poyck PP, Mareels G, Hoekstra R, et al.: Enhanced oxygen availability improves liver-specific functions of the AMC bioartificial liver. Artif Organs 2008, 32: 116-126.
20. Agarwal S, Holton KL, Lanza R: Efficient differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells 2008, 26: 1117-1127.
21. Hay DC, Fletcher J, Payne C, et al.: Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. Proc Natl Acad Sci U S A 2008, 105: 12301-12306.
22. McLean AB, D'Amour KA, Jones KL, et al.: Activin A efficiently specifies definitive endoderm from human embryonic stem cells only when phosphatidylinositol 3-kinase signaling is suppressed. Stem Cells 2007, 25: 29-38.
23. Kubo A, Shinozaki K, Shannon JM, et al.: Development of definitive endoderm from embryonic stem cells in culture. Development 2004, 131: 1651-1662.
24. Schmelzer E, Wauthier E, Reid LM: The phenotypes of pluripotent human hepatic progenitors. Stem Cells 2006, 24: 1852-1858.
25. Schmelzer E, Zhang L, Bruce A, et al.: Human hepatic stem cells from fetal and postnatal donors. J Exp Med 2007, 204: 1973-1987.
26. Stadlbauer V, Davies NA, Sen S, Jalan R: Artificial liver support systems in the management of complications of cirrhosis. Semin Liver Dis 2008, 28: 96-109.
27. McKenzie TJ, Lillegard JB, Nyberg SL: Artificial and bioartificial liver support. Semin Liver Dis 2008, 28: 210-217.
28. Rozga J: Liver support technology - an update. Xenotransplantation 2006, 13: 380-389.
29. Hassanein TI, Tofteng F, Brown RS Jr, et al.: Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007, 46: 1853-1862.
30. Ellis AJ, Hughes RD, Wendon JA, et al.: Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996, 24: 1446-1451.
31. Sussman NL, Finegold MJ, Barish JP, Kelly JH: A case of syncytial giant-cell hepatitis treated with an extracorporeal liver assist device. Am J Gastroenterol 1994, 89: 1077-1082.
32. Sussman NL, Kelly JH: Improved liver function following treatment with an extracorporeal liver assist device. Artif Organs 1993, 17: 27-30.